Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Medtronic plcMDT · Entity 2888 | EVP & Group President Diabetes | September 10, 2019 | September 12, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Medtronic plc
Report date September 10, 2019 · Filed September 12, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 30,761 |
Ending reported balance
After 2019-09-10 transaction · row 17
17 source rows · reconciled sequenceRow 1 · 2019-09-10 · Sale · Disposed 10,000 · Balance 30,761 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.00 to $107.39, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 2 · 2019-09-10 · Exercise / conversion · Acquired 10,257 · Balance 41,018 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Row 3 · 2019-09-10 · Sale · Disposed 10,257 · Balance 30,761 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.10 to $107.43, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 4 · 2019-09-10 · Exercise / conversion · Acquired 321 · Balance 31,082 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Row 5 · 2019-09-10 · Sale · Disposed 321 · Balance 30,761 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Row 6 · 2019-09-10 · Exercise / conversion · Acquired 27,254 · Balance 58,015 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Row 7 · 2019-09-10 · Sale · Disposed 27,254 · Balance 30,761 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.07 to $107.47, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 8 · 2019-09-10 · Exercise / conversion · Acquired 852 · Balance 31,613 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Row 9 · 2019-09-10 · Sale · Disposed 852 · Balance 30,761 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Row 10 · 2019-09-10 · Exercise / conversion · Acquired 19,054 · Balance 49,815 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Row 11 · 2019-09-10 · Sale · Disposed 19,054 · Balance 30,761 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.28 to $107.58, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 12 · 2019-09-10 · Exercise / conversion · Acquired 595 · Balance 31,356 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Row 13 · 2019-09-10 · Sale · Disposed 595 · Balance 30,761 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Row 14 · 2019-09-10 · Exercise / conversion · Acquired 14,121 · Balance 44,882 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Row 15 · 2019-09-10 · Sale · Disposed 14,121 · Balance 30,761 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.36 to $107.48, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 16 · 2019-09-10 · Exercise / conversion · Acquired 423 · Balance 31,184 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Row 17 · 2019-09-10 · Sale · Disposed 423 · Balance 30,761 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $78.00 · Expires 2025-08-03 | Direct | 321 |
Reported balance
After 2019-09-10 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2019-09-10 · Exercise / conversion · Disposed 10,257 · Balance 321 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7: These options to purchase ordinary shares of New Medtronic for $62.76 per share, which were unvested at the effective time of the Merger, were received in the Merger and represent the conversion of an equal number of Medtronic common stock shares for $62.76 per share. The New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. These options became exercisable in four equal annual installments beginning on July 28, 2015, which was the first anniversary of the grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $78.00 · Expires 2025-08-03 | Direct | 0 |
Reported balance
After 2019-09-10 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2019-09-10 · Exercise / conversion · Disposed 321 · Balance 0 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7: These options to purchase ordinary shares of New Medtronic for $62.76 per share, which were unvested at the effective time of the Merger, were received in the Merger and represent the conversion of an equal number of Medtronic common stock shares for $62.76 per share. The New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. These options became exercisable in four equal annual installments beginning on July 28, 2015, which was the first anniversary of the grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.06 · Expires 2026-08-01 | Direct | 9,085 |
Reported balance
After 2019-09-10 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2019-09-10 · Exercise / conversion · Disposed 27,254 · Balance 9,085 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.06 · Expires 2026-08-01 | Direct | 284 |
Reported balance
After 2019-09-10 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2019-09-10 · Exercise / conversion · Disposed 852 · Balance 284 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $83.97 · Expires 2027-07-31 | Direct | 19,055 |
Reported balance
After 2019-09-10 transaction · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · 2019-09-10 · Exercise / conversion · Disposed 19,054 · Balance 19,055 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $83.97 · Expires 2027-07-31 | Direct | 596 |
Reported balance
After 2019-09-10 transaction · row 23
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 23 · 2019-09-10 · Exercise / conversion · Disposed 595 · Balance 596 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $89.08 · Expires 2028-07-30 | Direct | 42,364 |
Reported balance
After 2019-09-10 transaction · row 24
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 24 · 2019-09-10 · Exercise / conversion · Disposed 14,121 · Balance 42,364 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $89.08 · Expires 2028-07-30 | Direct | 1,272 |
Reported balance
After 2019-09-10 transaction · row 25
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 25 · 2019-09-10 · Exercise / conversion · Disposed 423 · Balance 1,272 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.00 to $107.39, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.10 to $107.43, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.07 to $107.47, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.28 to $107.58, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.36 to $107.48, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F7: These options to purchase ordinary shares of New Medtronic for $62.76 per share, which were unvested at the effective time of the Merger, were received in the Merger and represent the conversion of an equal number of Medtronic common stock shares for $62.76 per share. The New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. These options became exercisable in four equal annual installments beginning on July 28, 2015, which was the first anniversary of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2017 Filed Aug 2, 2017 14:56 UTC | Medtronic plc MDT · Entity 2888 | GrantStock Option (Right to Buy) · Derivative | 1,191 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-17-024707 · form4.xml · derivative · entry 3 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,191 Underlying: Ordinary Shares · 1,191 shares Expires 2027-07-31 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 14:56 UTC | Medtronic plc MDT · Entity 2888 | GrantStock Option (Right to Buy) · Derivative | 38,109 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-17-024707 · form4.xml · derivative · entry 2 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,109 Underlying: Ordinary Shares · 38,109 shares Expires 2027-07-31 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 14:56 UTC | Medtronic plc MDT · Entity 2888 | GrantOrdinary Shares | 9,528 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-024707 · form4.xml · nonDerivative · entry 1 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,473 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share growth during the 36 month period ending on the last day of the Company's fiscal year 2020 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 12:45 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 3,914 | $84.29 | $329,911.06 |
DisclosureSEC source: 0001127602-17-024471 · form4.xml · nonDerivative · entry 1 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,945 F1 · balance_after: This balance increased by 930 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 13:57 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 36,648 | $0.00 Strike: $62.76 | $0.00 |
DisclosureSEC source: 0001127602-17-010410 · form4.xml · derivative · entry 7 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,317 Underlying: Ordinary Shares · 36,648 shares Expires 2024-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option to purchase 73,296 New Medtronic ordinary shares for $62.76 per share, which was unvested at the effective time of the Merger, was received in the Merger and represents the conversion of 73,296 Medtronic common stock shares for $62.76 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 13:57 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 797 | $0.00 Strike: $62.76 | $0.00 |
DisclosureSEC source: 0001127602-17-010410 · form4.xml · derivative · entry 6 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,965 Underlying: Ordinary Shares · 797 shares Expires 2024-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option to purchase 1,594 ordinary shares of New Medtronic for $62.76 per share, which was unvested at the effective time of the Merger, was received in the Merger and represents the conversion of 1,594 Medtronic common stock shares for $62.76 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 13:57 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,871 | $0.00 Strike: $62.76 | $0.00 |
DisclosureSEC source: 0001127602-17-010410 · form4.xml · derivative · entry 5 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,762 Underlying: Ordinary Shares · 14,871 shares Expires 2024-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option to purchase 29,743 New Medtronic ordinary shares for $62.76 per share, which was unvested at the effective time of the Merger, was received in the Merger and represents the conversion of 29,743 Medtronic common stock shares for $62.76 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 13:57 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 52,316 | $82.33 | $4,307,019.33 |
DisclosureSEC source: 0001127602-17-010410 · form4.xml · nonDerivative · entry 4 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,929 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.30 to $82.41, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: This balance increased by 627 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 13:57 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionOrdinary Shares | 36,648 | $62.76 | $2,300,028.48 |
DisclosureSEC source: 0001127602-17-010410 · form4.xml · nonDerivative · entry 3 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 13:57 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionOrdinary Shares | 797 | $62.76 | $50,019.72 |
DisclosureSEC source: 0001127602-17-010410 · form4.xml · nonDerivative · entry 2 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 13:57 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionOrdinary Shares | 14,871 | $62.76 | $933,303.96 |
DisclosureSEC source: 0001127602-17-010410 · form4.xml · nonDerivative · entry 1 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.